Phillip Pang - Jul 20, 2022 Form 4 Insider Report for Vir Biotechnology, Inc. (VIR)

Role: Chief Medical Officer
Signature: /s/ Howard Horn, Attorney-in-Fact
Stock symbol: VIR
Transactions as of: Jul 20, 2022
Transactions value $: -$142,125
Form type: 4
Date filed: 7/21/2022, 04:10 PM
Previous filing: Jun 22, 2022
Next filing: Jan 25, 2023

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	VIR	Common Stock	Award	$7.88K	+5K	+3.47%	$1.58^*	149K	Jul 20, 2022	Direct
transaction	VIR	Common Stock	Sale	-$150K	-5K	-3.36%	$30.00	144K	Jul 20, 2022	Direct	F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	VIR	Stock Option (Right to Buy)	Options Exercise	$0	-5K	-11.37%	$0.00	39K	Jul 20, 2022	Common Stock	5K	$1.58	Direct	F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on April 28, 2022.
F2	The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.00 to $30.03, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
F3	1/4 of the shares subject to the stock option vested and became exercisable on July 19, 2019, and the remaining shares vest in 36 equal monthly installments thereafter.